[1]
Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, Zheng ZJ, Flegal K, O'Donnell C, Kittner S, Lloyd-Jones D, Goff DC Jr, Hong Y, Adams R, Friday G, Furie K, Gorelick P, Kissela B, Marler J, Meigs J, Roger V, Sidney S, Sorlie P, Steinberger J, Wasserthiel-Smoller S, Wilson M, Wolf P, American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006 Feb 14:113(6):e85-151
[PubMed PMID: 16407573]
[2]
Hill JA, Olson EN. Cardiac plasticity. The New England journal of medicine. 2008 Mar 27:358(13):1370-80. doi: 10.1056/NEJMra072139. Epub
[PubMed PMID: 18367740]
[3]
Carlsson L, Duker G, Jacobson I. New pharmacological targets and treatments for atrial fibrillation. Trends in pharmacological sciences. 2010 Aug:31(8):364-71. doi: 10.1016/j.tips.2010.05.001. Epub 2010 May 31
[PubMed PMID: 20605645]
[4]
Milliken MC, Stray-Gundersen J, Peshock RM, Katz J, Mitchell JH. Left ventricular mass as determined by magnetic resonance imaging in male endurance athletes. The American journal of cardiology. 1988 Aug 1:62(4):301-5
[PubMed PMID: 2969673]
[5]
Rockman HA, Ross RS, Harris AN, Knowlton KU, Steinhelper ME, Field LJ, Ross J Jr, Chien KR. Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. Proceedings of the National Academy of Sciences of the United States of America. 1991 Sep 15:88(18):8277-81
[PubMed PMID: 1832775]
[6]
Lorell BH, Carabello BA. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation. 2000 Jul 25:102(4):470-9
[PubMed PMID: 10908222]
[7]
Dorn GW 2nd. The fuzzy logic of physiological cardiac hypertrophy. Hypertension (Dallas, Tex. : 1979). 2007 May:49(5):962-70
[PubMed PMID: 17389260]
[8]
Oros A, Beekman JD, Vos MA. The canine model with chronic, complete atrio-ventricular block. Pharmacology & therapeutics. 2008 Aug:119(2):168-78. doi: 10.1016/j.pharmthera.2008.03.006. Epub 2008 Apr 6
[PubMed PMID: 18514320]
[9]
Stambler BS. Tachycardia-induced ventricular electrical remodeling: a perspective on unresolved experimental mechanisms and clinical implications. Heart rhythm. 2006 Nov:3(11):1378-81
[PubMed PMID: 17074649]
Level 3 (low-level) evidence
[10]
Spragg DD, Akar FG, Helm RH, Tunin RS, Tomaselli GF, Kass DA. Abnormal conduction and repolarization in late-activated myocardium of dyssynchronously contracting hearts. Cardiovascular research. 2005 Jul 1:67(1):77-86
[PubMed PMID: 15885674]
[11]
Reis Filho JR, Cardoso JN, Cardoso CM, Pereira-Barretto AC. Reverse Cardiac Remodeling: A Marker of Better Prognosis in Heart Failure. Arquivos brasileiros de cardiologia. 2015 Jun:104(6):502-6. doi: 10.5935/abc.20150025. Epub 2015 Mar 27
[PubMed PMID: 26131706]
[12]
Aiba T, Tomaselli GF. Electrical remodeling in the failing heart. Current opinion in cardiology. 2010 Jan:25(1):29-36. doi: 10.1097/HCO.0b013e328333d3d6. Epub
[PubMed PMID: 19907317]
Level 3 (low-level) evidence
[13]
Lalonde L, Goudreau J, Hudon É, Lussier MT, Bareil C, Duhamel F, Lévesque L, Turcotte A, Lalonde G, Group for TRANSIT to Best Practices in Cardiovascular Disease Prevention in Primary Care. Development of an interprofessional program for cardiovascular prevention in primary care: A participatory research approach. SAGE open medicine. 2014:2():2050312114522788. doi: 10.1177/2050312114522788. Epub 2014 Feb 17
[PubMed PMID: 26770705]
[14]
El Hajj MS, Mahfoud ZR, Al Suwaidi J, Alkhiyami D, Alasmar AR. Role of pharmacist in cardiovascular disease-related health promotion and in hypertension and dyslipidemia management: a cross-sectional study in the State of Qatar. Journal of evaluation in clinical practice. 2016 Jun:22(3):329-40. doi: 10.1111/jep.12477. Epub 2015 Nov 10
[PubMed PMID: 26552842]
Level 2 (mid-level) evidence